PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Leqembi Approved as First Treatment to Slow Early Alzheimer’s Progression

European Commission grants authorisation for Eisai and Biogen therapy

The European Commission has granted marketing authorisation for Leqembi (lecanemab), making it the first therapy in the EU to slow the progression of early Alzheimer’s disease.

Lecanemab is indicated for adults with mild cognitive impairment or mild dementia due to Alzheimer’s who are apolipoprotein E ε4 non-carriers or heterozygotes with confirmed amyloid pathology.

The approval is based on phase 3 data from the Clarity AD trial, which demonstrated that lecanemab slowed disease progression compared with placebo over 18 months.

Gary Hendler, regional chairman and CEO at Eisai EMEA, said: “Today’s decision makes lecanemab the first treatment option in the European Union that can slow the progression of early Alzheimer’s disease and is a key step to making the medicine available to eligible patients.”

The decision applies to all 27 EU member states, as well as Iceland, Liechtenstein and Norway. Eisai will work with reimbursement authorities to ensure timely access.

The drug targets amyloid-beta protofibrils, a toxic form of amyloid that accumulates in the brain and contributes to cognitive decline.

Nick Burgin, president and COO at Eisai EMEA, added: “Achieving optimal outcomes for people treated with the medicine is of paramount importance.”

Biogen’s president for Europe, Wolfram Schmidt, called the approval a milestone in tackling Alzheimer’s.

The most common adverse events observed in the Clarity AD trial included infusion-related reactions, amyloid-related imaging abnormalities, headaches and cerebral oedema.

Eisai leads global development and regulatory submissions for lecanemab, co-commercialising with Biogen. The company aims to ensure appropriate use of the drug in each country where it is introduced.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026